Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-06 | Lilly Endowment Inc.Unternehmen | -15,83k | 15,75M | Verkauf | 995,23 - 996,18 | 91,88M | -0,02% |
| 2026-02-19 | Mr. Eric DozierExec. VP & CPO | -481,00 | 0,00 | Other Disposition | - | 14,84k | -3,14% |
| 2026-02-16 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | 102,45 | 0,00 | Derivative Exercise and Retained Stock | - | 5,25k | 1,99% |
| 2026-02-16 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -81,55 | 84,82k | Derivative Exercise and Sale | 1,04k | 5,25k | - |
| 2026-02-16 | Mr. Lucas E. MontarceExec. VP & CFO | 208,27 | 0,00 | Derivative Exercise and Retained Stock | - | 16,26k | 1,30% |
| 2026-02-16 | Mr. Lucas E. MontarceExec. VP & CFO | -159,73 | 166,12k | Derivative Exercise and Sale | 1,04k | 16,26k | - |
| 2026-02-16 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | 115,69 | 0,00 | Derivative Exercise and Retained Stock | - | 10,14k | 1,15% |
| 2026-02-16 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | -91,31 | 94,96k | Derivative Exercise and Sale | 1,04k | 10,14k | - |
| 2026-02-16 | Ms. Adrienne BrownExec. VP & President of Lilly Immunology | 221,03 | 0,00 | Derivative Exercise and Retained Stock | - | 5,14k | 4,49% |
| 2026-02-16 | Ms. Adrienne BrownExec. VP & President of Lilly Immunology | -169,97 | 176,76k | Derivative Exercise and Sale | 1,04k | 5,14k | - |
| 2026-02-01 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | 1,88k | 0,00 | Derivative Exercise and Retained Stock | - | 28,14k | 7,17% |
| 2026-02-01 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | -1,51k | 1,57M | Derivative Exercise and Sale | 1,04k | 28,14k | - |
| 2026-02-01 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | 7,04k | 0,00 | Derivative Exercise and Retained Stock | - | 220,14k | 3,30% |
| 2026-02-01 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | -5,64k | 5,85M | Derivative Exercise and Sale | 1,04k | 220,14k | - |
| 2026-02-01 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | 2,20k | 0,00 | Derivative Exercise and Retained Stock | - | 31,41k | 7,53% |
| 2026-02-01 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | -1,91k | 1,98M | Derivative Exercise and Sale | 1,04k | 31,41k | - |
| 2026-02-01 | Mr. Diogo RauExec. VP and Chief Information & Digital Officer | 2,08k | 0,00 | Derivative Exercise and Retained Stock | - | 21,80k | 10,54% |
| 2026-02-01 | Mr. Diogo RauExec. VP and Chief Information & Digital Officer | -1,67k | 1,74M | Derivative Exercise and Sale | 1,04k | 21,80k | - |
| 2026-02-01 | Mr. David A. RicksChairman & CEO | 17,64k | 0,00 | Derivative Exercise and Retained Stock | - | 751,81k | 2,40% |
| 2026-02-01 | Mr. David A. RicksChairman & CEO | -14,30k | 14,83M | Derivative Exercise and Sale | 1,04k | 751,81k | - |
| 2026-02-01 | Mr. Patrik JonssonExec. VP & President of Lilly International | 2,18k | 0,00 | Derivative Exercise and Retained Stock | - | 56,44k | 4,01% |
| 2026-02-01 | Mr. Patrik JonssonExec. VP & President of Lilly International | -1,75k | 1,82M | Derivative Exercise and Sale | 1,04k | 56,44k | - |
| 2026-02-01 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | 1,98k | 0,00 | Derivative Exercise and Retained Stock | - | 42,58k | 4,88% |
| 2026-02-01 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | -1,59k | 1,65M | Derivative Exercise and Sale | 1,04k | 42,58k | - |
| 2026-02-01 | Ms. Anat HakimExec. VP, General Counsel & Secretary | 3,75k | 0,00 | Derivative Exercise and Retained Stock | - | 47,28k | 8,61% |
| 2026-02-01 | Ms. Anat HakimExec. VP, General Counsel & Secretary | -2,95k | 3,06M | Derivative Exercise and Sale | 1,04k | 47,28k | - |
| 2026-02-01 | Mr. Eric DozierExec. VP & CPO | 1,59k | 0,00 | Derivative Exercise and Retained Stock | - | 11,80k | 15,51% |
| 2026-02-01 | Mr. Eric DozierExec. VP & CPO | -1,27k | 1,32M | Derivative Exercise and Sale | 1,04k | 11,80k | - |
| 2026-01-07 | Lilly Endowment Inc.Unternehmen | -292,15k | 322,38M | Verkauf | 1,09k - 1,12k | 91,90M | -0,32% |
| 2026-01-05 | Lilly Endowment Inc.Unternehmen | -1,39k | 1,51M | Verkauf | 1,09k | 92,19M | -0,00% |
| 2025-12-29 | Lilly Endowment Inc.Unternehmen | -3,59k | 3,90M | Verkauf | 1,09k | 92,19M | -0,00% |
| 2025-12-23 | Lilly Endowment Inc.Unternehmen | -2,87k | 3,11M | Verkauf | 1,09k | 92,19M | -0,00% |
| 2025-11-25 | Lilly Endowment Inc.Unternehmen | -162,69k | 178,42M | Verkauf | 1,07k - 1,11k | 92,20M | -0,18% |
| 2025-11-24 | Lilly Endowment Inc.Unternehmen | -142,31k | 152,06M | Verkauf | 1,07k | 92,36M | -0,15% |
| 2025-11-21 | Lilly Endowment Inc.Unternehmen | -105,33k | 111,50M | Verkauf | 1,05k - 1,07k | 92,50M | -0,11% |
| 2025-11-20 | Lilly Endowment Inc.Unternehmen | -37,15k | 39,07M | Verkauf | 1,05k - 1,06k | 92,61M | -0,04% |
| 2025-11-19 | Lilly Endowment Inc.Unternehmen | -167,53k | 176,10M | Verkauf | 1,05k - 1,06k | 92,64M | -0,18% |
| 2025-11-18 | Lilly Endowment Inc.Unternehmen | -60,21k | 62,31M | Verkauf | 1,03k - 1,04k | 92,81M | -0,06% |
| 2025-11-17 | Lilly Endowment Inc.Unternehmen | -9,89k | 10,19M | Verkauf | 1,03k | 92,87M | -0,01% |
| 2025-11-14 | Lilly Endowment Inc.Unternehmen | -178,30k | 183,80M | Verkauf | 1,03k | 92,88M | -0,19% |
| 2025-11-13 | Lilly Endowment Inc.Unternehmen | -46,61k | 48,02M | Verkauf | 1,03k | 93,06M | -0,05% |
| 2025-11-13 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -1.000,00 | 1,01M | Automatic Disposition | 1,01k | 4,57k | -17,96% |
| 2025-11-12 | Lilly Endowment Inc.Unternehmen | -305,00k | 308,41M | Verkauf | 1,00k - 1,02k | 93,11M | -0,33% |
| 2025-11-10 | Lilly Endowment Inc.Unternehmen | -300,00k | 295,75M | Verkauf | 972,17 - 999,09 | 93,41M | -0,32% |
| 2025-11-10 | Mr. David A. RicksChairman & CEO | -24,75k | 0,00 | Other Disposition | - | 734,17k | -3,26% |
| 2025-11-10 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | -179,00 | 0,00 | Other Disposition | - | 213,10k | -0,08% |
| 2025-11-05 | Lilly Endowment Inc.Unternehmen | -219,47k | 205,57M | Verkauf | 911,01 - 954,95 | 93,71M | -0,23% |
| 2025-11-04 | Lilly Endowment Inc.Unternehmen | -526,00 | 479,04k | Verkauf | 910,72 | 93,93M | -0,00% |
| 2025-11-03 | Lilly Endowment Inc.Unternehmen | -300,00k | 266,65M | Verkauf | 877,40 - 900,79 | 93,93M | -0,32% |
| 2025-10-31 | Lilly Endowment Inc.Unternehmen | -301,34k | 260,17M | Verkauf | 862,63 - 869,47 | 94,23M | -0,32% |
| 2025-10-10 | Lilly Endowment Inc.Unternehmen | -3,66k | 3,16M | Verkauf | 862,34 - 863,37 | 94,53M | -0,00% |
| 2025-10-09 | Lilly Endowment Inc.Unternehmen | -10,60k | 9,04M | Verkauf | 848,63 - 857,26 | 94,54M | -0,01% |
| 2025-10-08 | Lilly Endowment Inc.Unternehmen | -101,42k | 86,23M | Verkauf | 848,46 - 856,00 | 94,55M | -0,11% |
| 2025-10-07 | Lilly Endowment Inc.Unternehmen | -26,80k | 22,72M | Verkauf | 848,01 | 94,65M | -0,03% |
| 2025-10-06 | Lilly Endowment Inc.Unternehmen | -161,18k | 137,04M | Verkauf | 848,30 - 855,71 | 94,68M | -0,17% |
| 2025-10-03 | Lilly Endowment Inc.Unternehmen | -192,40k | 161,22M | Verkauf | 821,42 - 847,60 | 94,84M | -0,20% |
| 2025-10-02 | Lilly Endowment Inc.Unternehmen | -112,60k | 92,50M | Verkauf | 821,09 - 833,92 | 95,03M | -0,12% |
| 2025-10-01 | Lilly Endowment Inc.Unternehmen | -351,02k | 284,65M | Verkauf | 765,75 - 833,15 | 95,14M | -0,37% |
| 2025-09-30 | Lilly Endowment Inc.Unternehmen | -113,69k | 86,79M | Verkauf | 763,10 - 766,12 | 95,49M | -0,12% |
| 2025-09-19 | Lilly Endowment Inc.Unternehmen | -23,67k | 18,06M | Verkauf | 763,05 - 764,47 | 95,61M | -0,02% |
| 2025-09-18 | Lilly Endowment Inc.Unternehmen | -106,63k | 81,53M | Verkauf | 763,29 - 767,07 | 95,63M | -0,11% |
| 2025-09-05 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | -17,00 | 0,00 | Other Disposition | - | 40,60k | -0,04% |
| 2025-08-27 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | 612,94 | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 2,17k | 39,29% |
| 2025-08-28 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -1.000,00 | 734,93k | Automatic Disposition | 734,93 | 5,57k | -15,23% |
| 2025-08-15 | Mr. Lucas E. MontarceExec. VP & CFO | 715,00 | 494,63k | Kauf | 691,79 | 14,69k | 5,12% |
| 2025-08-13 | Mr. Ralph AlvarezIndependent Director | 758,00 | 500,47k | Kauf | 660,25 | 758,00 | - |
| 2025-08-13 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | 1.000,00 | 647,36k | Kauf | 647,36 | 29,21k | 3,55% |
| 2025-08-12 | Mr. David A. RicksChairman & CEO | 1,63k | 1,05M | Kauf | 644,77 | 758,91k | 0,22% |
| 2025-08-12 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | 1.000,00 | 634,41k | Kauf | 634,41 | 213,28k | 0,47% |
| 2025-08-12 | Ms. Gabrielle SulzbergerIndependent Director | 117,00 | 75,02k | Kauf | 641,18 | 2,70k | 4,52% |
| 2025-08-12 | Mr. Jon Erik FyrwaldIndependent Director | 1,57k | 1,01M | Kauf | 642,00 - 642,59 | 1,68k | 1.326,27% |
| 2025-08-11 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | -1,25k | 783,76k | Automatic Disposition | 627,01 | 26,26k | -4,54% |
| 2025-08-08 | Mr. Jamere JacksonIndependent Director | 200,00 | 127,91k | Kauf | 639,56 | 200,00 | - |
| 2025-08-01 | Ms. Melissa S. SeymourExec. VP of Global Quality | 525,08 | 0,00 | Derivative Exercise and Retained Stock | - | 525,00 | - |
| 2025-08-01 | Ms. Melissa S. SeymourExec. VP of Global Quality | -426,92 | 315,95k | Derivative Exercise and Sale | 740,07 | 525,00 | - |
| 2025-07-24 | Lilly Endowment Inc.Unternehmen | -280,00k | 225,42M | Verkauf | 803,48 - 808,34 | 95,74M | -0,29% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
